Prime Medicine received clearance from New Zealand’s Medsafe for the clinical trial application of PM-577a, an investigational Prime Editor for Wilson’s disease. The clearance advances the program toward human testing using a Prime Editing approach, which is a CRISPR-derived method designed to make targeted DNA changes. The company’s PM-577a is positioned to address Wilson’s disease by correcting underlying genetic causes through editor-mediated sequence targeting rather than traditional gene addition or full gene knockouts. With regulatory permission secured for the trial application, Prime Medicine can proceed with site and patient readiness for the study. The move highlights continued expansion of Prime Editing programs into broader geographies, with Medsafe clearance adding to the company’s progress toward clinical validation of its platform in rare genetic disease.